Results 111 to 120 of about 15,932 (195)
Obesity Reviews, EarlyView.ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira +8 more
wiley +1 more source
Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction
Obesity Reviews, EarlyView.Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey +7 more
wiley +1 more source
Improved Glucagon Sensitivity Following Weight Loss: A Systematic Review and Meta‐Analysis
Obesity Reviews, EarlyView.ABSTRACT Objective This systematic review and meta‐analysis investigated the effect of weight loss in people with obesity on two biomarkers of glucagon resistance: fasting plasma glucagon and alanine. Methods A comprehensive search was conducted in Medline and Embase. Random‐effects meta‐analyses and correlation analyses were performed.
Hye‐Rin Charlotte Kim +4 more
wiley +1 more source
Understanding exosomes in diabetic wound healing
Periodontology 2000, EarlyView.Abstract Background Diabetic wounds signify a major complication of diabetes mellitus, characterized by chronic inflammation, compromised angiogenesis, and high risk of infection, amputation, and mortality. Contemporary therapies remain limited in efficacy and durability.
Paras Ahmad +4 more
wiley +1 more source
Experimental Physiology, EarlyView.Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu +5 more
wiley +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend Overview of multiscale cardiac remodelling in type 2 diabetes and how to model and simulate these changes using a human‐based, multiscale computational framework. Cardiac remodelling in type 2 diabetes occurs at ionic channel, protein, cellular, tissue and whole‐organ level, affecting the electrophysiological function, mechanical
Ambre Bertrand +2 more
wiley +1 more source
Качественная клиническая практика, 2018 Objectives. To evaluate the cost-effectiveness of dapagliflozin in combination with metformin in the treatment T2DM in comparison with glimepiride and sitagliptin also combined with metformin. Methods.
S. K. Zyryanov +3 more
doaj
Natural History of Chronic Kidney Disease in Sickle Cell Disease
American Journal of Hematology, Volume 101, Issue 7, Page 1456-1477, July 2026.ABSTRACT Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. Increasing evidence suggests that the natural history of SCD nephropathy is progressive. Initial glomerular
Kenneth I. Ataga
wiley +1 more source
Effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes Mellitus and coronary heart disease. [PDF]
Front Cardiovasc MedLiu F, Jin R.
europepmc +1 more source
Dapagliflozin alleviates heart failure with preserved ejection fraction potentially by regulating the AIM2/caspase‑1/GSDMD pathway and attenuating pyroptosis. [PDF]
Mol Med RepDing S +5 more
europepmc +1 more source